AbbVie Exercises Option to License Parkinson’s Tech from BioArctic

The portfolio includes antibodies targeting pathological species of α-synuclein.

The research, development, option and license agreement that Swedish biopharma company BioArctic signed with drugmaker AbbVie in September 2016 is bearing fruit. The company has received clearance from the U.S. Federal Trade Commission (FTC) to out-license its α-synuclein antibody portfolio.

The original agreement focused on the development and commercialization of BioArctic’s antibody products targeting pathological species of α-synuclein for potential indications, including Parkinson’s. α-Synuclein gene mutations are believed to be associated with the development of Parkinson’s in certain patients who suffer from an inherited form of the condition.

BioArctic’s lead candidate is the α-synuclein antibody BAN0805, which is being developed as a disease-modifying therapy for Parkinson’s. The candidate, now referred to as ABBV-0805, will be taken into clinical development by AbbVie, with the first trial to be conducted in 2019. BioArctic will continue with other development activities outlined in the initial agreement.

The total value of the initial agreement is approximately $755 million, with additional royalties; AbbVie previously paid BioArctic $80 million. AbbVie’s choice to exercise its option will trigger an additional milestone payment of $50 million.


David Alvaro, Ph.D.

David is Scientific Editor in Chief of the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content, in addition to serving as Scientific Research Director for That's Nice. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University in 1999 and a Ph.D. in Genetics and Development from Columbia University in 2008.